The market for innovative drugs continues to expand, and funds are increasingly favoring the pharmaceutical sector listed via Stock Connect on the Hong Kong stock exchange.
Release time:
2023-03-02
According to a report by the Prospect Industry Research Institute, driven by favorable policies, dynamic adjustments to medical insurance coverage, and increased R&D investment, China’s innovative drug market is experiencing rapid growth.
According to a report by the Prospect Industry Research Institute, driven by favorable policies, dynamic adjustments to medical insurance coverage, and increased R&D investment, China’s innovative drug market has experienced rapid growth. Preliminary statistics from Frost & Sullivan show that in 2024, the size of China’s innovative pharmaceutical industry exceeded 1.13 trillion yuan. As the market expands, the investment value of related indices has become increasingly prominent. The CSI Hong Kong Stock Connect Healthcare Index comprises 50 liquid, large-cap healthcare stocks listed within the Hong Kong Stock Connect program. Recently, the Hong Kong Stock Connect Healthcare ETF (513200) has seen net inflows for two consecutive weeks, totaling over 500 million yuan. Its low management fee—just 0.15% per year—has attracted numerous investors, making it an excellent choice for investing in leading companies in the pharmaceutical sector and reflecting the market’s continued optimism toward the pharmaceutical industry, particularly the innovative drug segment.
Address: 6th Floor, Building C6, Jiangsu Life Science and Technology Innovation Park, Qixia District, Nanjing City
Official account